TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Occurrence of HLA-DR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of DRB1*1501-positive genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of hypertension (HTN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DWI+ incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of sexual risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: symptomatic deep vein thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: nonfatal pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of potentially harmful medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital days per person per year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice Reaction Time (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of SPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of induction of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean section rates
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: cured-markedly effective rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements on physical signs of lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: symptoms as cough, dyspnea and sputum expectorating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total area under the plasma concentration-time curve of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of the M7 metabolite of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required for the maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intraoperative maternal complications
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative neonatal complications
Endpoint domain: Adverse events/effects
Primary endpoint: mean serum decorin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first clinically diagnosed AOM episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of children requiring additional bolus of sevoflurane for anesthesia maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of inspired and expired sevoflurane at the end of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS value upon awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight increase in female infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height increase in female infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diastolic bp drop on orthostatic challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Active TB cases
Endpoint domain: Mortality/survival
Primary endpoint: Alanine aminotransferase and aspartate aminotransferase elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HDL-C reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eating pathology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhibition of HIV and HSV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of OTM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of Social Anxiety Disorder (SAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aberrant Behavior Checklist total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lethargy and hyperactivity subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival flora reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cell-free hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BNP levels posttransfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Willingness to engage in infection control strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation with 3-month measures of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of residual bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of lymph node involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intensity of pain on injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for endotracheal intubation and invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain sensitivity to heat stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fluid evacuated daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drains-related pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma concentrations of factor VII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change from baseline in AIMS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Change‐TD rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Global Impression of Change rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annualized rate of stroke/SEE
Endpoint domain: Mortality/survival
Primary endpoint: Energy intake during ad libitum lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of serologically confirmed seasonal A/H1N1 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of serologically confirmed A/H3N2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of laboratory-confirmed pandemic A/H1N1 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Composite event occurrence
Endpoint domain: Mortality/survival
Primary endpoint: average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall medication assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting glucose and glycated haemoglobin within normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Speech difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Chewing difficulty
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fasting plasma concentrations of IL-1beta and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin response to the rye bread meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma glucose concentrations decrease below fasting concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: freedom from a decline in pulmonary function with bronchiolitis obliterans syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: freedom from biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PTPS
Endpoint domain: Mortality/survival
Primary endpoint: Need for pain therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative aesthetic result rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and acceptability of electronic data collection methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary composite outcome (cardiovascular death, myocardial infarction, and stroke)
Endpoint domain: Mortality/survival
Primary endpoint: geometric mean infarct growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Median time to receipt of benefits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median financial award
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Primary prevention of type 2 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: F30 performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health status QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total score of functions and symptoms of QoL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient satisfaction with advice received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom improvement after 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: F2-IsoP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical symptom distress scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic memory retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prescribing decisions for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of postoperative surgical wound infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete venous recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical or radiological thrombosis aggravation
Endpoint domain: Adverse events/effects
Primary endpoint: Major bleeding leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Percent weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants losing 10% of initial body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Micromorphology of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of DHT formation and elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 5 alpha‐reductase turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Potency of 5 alpha‐reductase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mPASI75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median TTTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary cross-sectional area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular occlusal area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular intermolar and interpremolar distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SV variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biofilm vitality reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Antiplatelet efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: free estradiol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SHBG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TEVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Referral of women with breast cancer to specialists for clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concerns about disadvantages to patients in clinical trials
Endpoint domain: Adverse events/effects
Primary endpoint: Desire for optimum treatment for patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to food intake resumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: average examination score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in micronuclei frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correction of basal hypokalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe hyponatremia and convulsions
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically relevant infections
Endpoint domain: Adverse events/effects
Primary endpoint: Enhancement of beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma GLP-1 gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inspiratory power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ca(OH)2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cleanliness of the isthmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general vitality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: work-related vitality
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: degree of wound infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of used dressings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reusable forceps malfunction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cost per use of forceps
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participation in second chance breakfast
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 35m sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohesive failure incidence in ceramic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean difference in therapeutic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMR-medication matching rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: live-birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Efficacy of agents for chemoprevention of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum HBV DNA negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir exposure at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness of TXLC in treating AP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of adenomatous polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: biochemical recurrence-free survival (BCRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Complete healing of fungal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean 6-month serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean estimated GFR (Nankivell)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: daytime sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: day/night sleep ratio
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: time to fall asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in asthmatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in drug intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in non-specific bronchial BHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous oxygen pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near infrared spectroscopy measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta2M concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta2M reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm blood flow responses to endothelium dependent and independent stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HIV RNA < or = 20 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24 h carbohydrate balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h fat balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative risk of developing RPOA type‐2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colony-Forming Units (CFU) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sensitivity of Microlux/DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of Microlux/DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive predictive value (PPV) of Microlux/DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated peripheral insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol:HDL-cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relapse rate in patients not depressed at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate in patients depressed at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rates after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological response to implant surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes